EI
NVCR icon

EAM Investors’s NovoCure NVCR Stock Holding History

EAM Investors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-141,893
Closed -$4.23M – 322
2024
Q4 		$4.23M Buy
+141,893
New +$3M 0.6% 73
2020
Q1 		– Sell
-19,534
Closed -$1.65M – 268
2019
Q4 		$1.65M Sell
19,534
-2,619
-12% -$211K 0.36% 122
2019
Q3 		$1.66M Sell
22,153
-2,691
-11% -$215K 0.44% 100
2019
Q2 		$1.57M Sell
24,844
-2,247
-8% -$114K 0.38% 107
2019
Q1 		$1.3M Buy
+27,091
New +$1.3M 0.32% 143
2018
Q4 		– Sell
-76,573
Closed -$4.01M – 305
2018
Q3 		$4.01M Sell
76,573
-25,200
-25% -$1M 0.6% 33
2018
Q2 		$3.19M Buy
+101,773
New +$2.83M 0.5% 76
2018
Q1 		– Sell
-117,668
Closed -$2.38M – 337
2017
Q4 		$2.38M Buy
+117,668
New +$2.27M 0.43% 103

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

EAM Investors's NVCR Position: Q1 2025 in Review

EAM Investors sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 141,893 shares — an estimated $4.23M sold.

EAM Investors first reported a position in NVCR in Q4 2017 and held it in 8 quarters. The position peaked at $4.23M in Q4 2024. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • EAM Investors reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
  • EAM Investors sold 141,893 NovoCure shares in Q1 2025, an estimated $4.23M.
  • EAM Investors first reported a position in NovoCure in Q4 2017 and held it in 8 quarters.
  • EAM Investors's NovoCure position peaked at $4.23M in Q4 2024.
  • 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on EAM Investors's 13F filing for Q1 2025, filed 13 May 2025.